Cortexyme, Inc.

106 articles with Cortexyme, Inc.

• Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development Program

  9/27/2018

  ortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting phase 2 clinical development in AD next year.

• 

  Alzheimer’s Company Cortexyme Closes $76 Million Series B Financing Round with Pfizer, Takeda and...

  5/31/2018

  South San Francisco-based Cortexyme closed on a $76 million Series B financing round.

• Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress

  5/31/2018

  Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388

• Cortexyme Initiates Phase I Clinical Development of COR388, a Promising Potential Treatment for Alzheimer’s and Other Degenerative Diseases

  1/4/2018

  Cortexyme today announced the first cohort has been dosed in the initial trial of its phase 1 clinical development program for COR388, the company’s lead compound.

• Cortexyme Raises $15 Million Series A

  1/6/2016

• Cortexyme Raises Seed Funding, Awarded Breakout Labs Investment

  6/12/2014